How many investments has Ascenta Capital made?

Ascenta Capital has 18 tracked investments, 1 of which have exited, including 3 dated in the last 24 months.

What stage does Ascenta Capital invest at?

Ascenta Capital invests at the Seed, Series A, Series B stages.

What is Ascenta Capital's typical check size?

Ascenta Capital typically writes checks of $15M – $30M.

What sectors does Ascenta Capital focus on?

Ascenta Capital focuses on Biotech, Healthtech.

Where is Ascenta Capital located?

Ascenta Capital is headquartered in Wilmington, US.

Does Ascenta Capital lead rounds?

Ascenta Capital has led 4 of the 4 rounds where its role is on record.

Who does Ascenta Capital co-invest with?

Ascenta Capital most often shares deals with OrbiMed, Lightspeed Venture Partners, RA Capital, among 40 tracked co-investors.

Ascenta Capital

Venture capital

Wilmington · Seed–Series B · 8 people tracked

Also known as ASCENTA CAPITAL MANAGEMENT CO., L.P.

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Ascenta Capital

2,855 people in our graph share verified history with the Ascenta Capital team — schools, employers, funds. One of them is your warm intro.

Jim Breyerunlockedknows Evan Rachlin · together at Blackstone Life Sciences (overlapped)

×2knows the team · via Moderna

×5knows the team · via Bain Capital Ventures

×4knows the team · via Third Rock Ventures

✨ Fox Verdict

Investment thesis

Ascenta Capital invests in biotech and life sciences companies, believing the current period offers an unprecedented convergence of biological and chemical insights, life science technology, data analytics, talent, and capital. The team combines deep drug development and clinical expertise with financial and operating backgrounds to identify and advance therapeutic opportunities across a range of therapeutic areas and modalities.

Invests inBiotech Healthtech Global Wilmington

Source: firm website, verified Sep 22, 2026.

Stage

Seed–Series B

Check

$15M – $30M

Wilmington, US

Instruments

Equity

Founded

2023

Last 12 months

1 investment

AUM

$335M

VC funds

Tracked investments

Acquisitions

Team · 8 people

from the firm's website & public directories

Evan Rachlin· Co-Founder and Managing Partner· United Statesin

Co-founder and Managing Partner of Ascenta Capital, co-leading the firm with Lorence Kim. He was previously a Managing Director at Blackstone Life Sciences, Head of Strategy at Moderna, and a Principal at Bain Capital Ventures, starting his career at McKinsey and Pfizer. He holds an A.B. from Harvard and an M.D. from Harvard Medical School.

Lorence Kim· Co-Founder and Advisory Partner· New York, New York, United Statesin

Co-founder and Advisory Partner of Ascenta Capital. He was previously a Venture Partner at Third Rock Ventures and CFO of Moderna, and earlier a managing director co-heading US biotech investment banking at Goldman Sachs. He holds an A.B. from Harvard, an MBA from Wharton, and an MD from the University of Pennsylvania.

Daniel Bloomfield· Partner

Partner at Ascenta Capital with over 20 years in pharma and biotech drug development. He was most recently CMO of Anthos Therapeutics and previously first CEO of Cardurion Pharmaceutical, following a 14-year career at Merck. He trained as a physician and cardiologist and holds degrees from Haverford, Oxford (Rhodes Scholar), and Harvard Medical School.

Jeff Chodakewitz· Partnerin

Partner at Ascenta Capital with 30+ years in pharma and biotech. He held senior development roles at Merck including VP of Infectious Diseases & Vaccines, then served as CMO and EVP at Vertex. He later advised Blackstone Life Sciences and serves on public company boards. He holds a B.S. and M.D. from Yale.

Michael Rosenblatt· Partner

Partner at Ascenta Capital who has held major leadership roles across pharma, academia and biotech. He was CMO of Merck and of Flagship Pioneering, and Dean of Tufts University School of Medicine. He graduated from Columbia and earned an MD from Harvard.

Paul Deutsch· Partner

Partner at Ascenta with 31 years in Translational Medicine and Early Development at Merck and Sanofi, most recently as Senior VP, Global Head of Translational Medicine and Early Development at Sanofi. He holds an A.B. from Harvard and an MD/PhD from Albert Einstein College of Medicine.

John Gutierrez· Principalin

Principal at Ascenta Capital who joined at the firm's inception in 2023 and focuses on sourcing and evaluating new investments. He was previously a Senior Associate in healthcare investment banking at Goldman Sachs. He holds an M.D. from Columbia, an MBA from Columbia Business School, and a B.A. from the University of Florida.

Leighanne Oh· Vice Presidentin

Vice President at Ascenta Capital who joined in 2024 and focuses on sourcing and evaluating new investments. She previously invested in biotech and life sciences at Novo Holdings and Sofinnova Investments, and began her career in healthcare investment banking at Jefferies. She holds M.S. and B.S.E. degrees in Biomedical Engineering from Duke.

What they invest in

from 13 of 18 portfolio companies

Biotech ×12Medical Devices ×7Healthtech ×5Deep Tech ×3Digital Health ×3AI & Machine Learning ×1Fintech ×1Longevity ×1

HQs:United States×10Canada×1

Investments · 18 tracked

founders shown can be your intro path

By year:2025 · 2 2024 · 3 2023 · 49 dated

Iambiciambic.ai in✓ verified

Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.

AI & Machine LearningBiotechDeep TechSan Diego, US

Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)in Thomas Miller(Founder)in Chao Zhang(Executive Officer)inTabbert Teng(Executive Officer)Neil Josephson(Chief Medical Officer)in

Co-investorsAbingworth Catalio Capital Management Alumni Ventures Catalio Capital Management, LP Coatue Management Eisai Innovation, Inc.+6 more

OrsoBioorsobio.com in 𝕏✓ verified

OrsoBio develops therapies to restore energy homeostasis in patients with severe metabolic disorders, drawing on biological research including human liver organoids and insights from metabolic pathways.

BiotechDeep TechMedical DevicesMenlo Park, US

Mani Subramanian(Executive Officer, Director)inGangadhara Ganapati(Executive Officer, Director)Dr. SubramanianDr. Myers

Board Matthew Young(Director)in Srinivas Akkaraju(Director)

Co-investorsLongitude Capital Samsara BioCapital F-Prime Capital

Triana Biotrianabio.com in 𝕏✓ verified

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & Chief Executive Officer)in

Co-investorsAtlas Venture Lightspeed Venture Partners RA Capital Bessemer Venture Partners Pfizer Ventures Finchley Healthcare Ventures +3 more

ADARx Pharmaceuticalsadarx.com inAug 2023

ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.

BiotechHealthtechMedical DevicesSan Diego, US

Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)in Robert A. MacLeod(Chief Scientific Officer)in Christopher Claeboe(Senior Vice President of Operations)in

Board seatLorence Kim· per SEC Form D

Co-investorsBain Capital Life Sciences OrbiMed SR One Capital Management Lilly Asia Ventures T. Rowe Price TCG Crossover +3 more

Odyssey Therapeuticsodysseytx.com in 𝕏Dec 2023

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)in

Board Jill Carroll(Director)in Carl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)in

Board seatLorence Kim· per SEC Form D

Co-investorsActivant Capital Balderton Capital Catalio Capital Management, LP Foresite Capital Global BioAccess Fund GreatPoint Ventures +8 more

4646.capitalJan 2023 · $46M

46 Capital is an investment firm focused on early-stage companies across multiple sectors, led by experienced professionals with backgrounds in venture capital, private equity, healthcare, energy, and finance.

Fintech

Tim Clark(Managing Director)

Co-investorsHurricane Ventures Andreessen Horowitz Avaana Capital BoxGroup Claypond Capital First Round Capital +7 more

Alpha-9 Oncologya9oncology.com inOct 2024

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen Horowitz Delos Capital General Catalyst Lightspeed Venture Partners Longitude Capital Lumira Ventures +9 more

Alpha-9 Theranostics Inc.alpha9tx.com inJan 2024

Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.

BiotechLongevityMedical Devices

Co-investorsFrazier Life Sciences WUTIF Capital Biotechnology Value Fund Lightspeed Venture Partners Longitude Capital Nextech Invest +1 more

Angitia Bioangitiabio.com

Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and related diseases.

Biotech

Co-investorsFrazier Life Sciences OrbiMed RA Capital Frazier

Cardurioncardurion.com inJul 2024 · $260M

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization.

BiotechDigital HealthHealthtechMedical DevicesBurlington, US

Michael E. Mendelsohn(Founder and Chief Strategy Officer)in Michael Mendelsohn, M.D.(Founder)in

Co-investorsBain Capital Delos Capital Digitalis Ventures New Enterprise Associates (NEA)Bain Capital Life Sciences Bain Capital Tech Opportunities +4 more

Latigo Biolatigobio.comJan 2025

Latigo Biotherapeutics is a clinical-stage biopharmaceutical company developing non-opioid pain medicines designed to stop pain transmission without addiction risk.

BiotechHealthtechMedical DevicesThousand Oaks, US

Nima Farzan(Executive Officer, Director)Tim Lugo(Executive Officer)

Board Beth Seidenberg(Director)in Jim Tananbaum(Director)in Deborah Palestrant(Director)inKevin Raidy(Director)

Co-investors5AM Ventures Access Biotechnology Foresite Capital Kern Capital, LLC Sanofi Ventures Westlake Village BioPartners

Trivenitriveni.bio in

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.

BiotechDigital HealthHealthtech

Vishal Patel in

Co-investorsAtlas Venture Borealis Ventures Borealis Ventures Magnetic Ventures OrbiMed Fidelity Investments +3 more

Tubulis GmbHtubulis.com in 𝕏acquired by Gilead Sciences

The page is a placeholder shell showing only cookie/consent notices for embedded third-party content (Vimeo, YouTube, reCAPTCHA, social media) and contains no substantive information about the company.

Dominik Schumacher(Founder)in

Co-investorsAndera Partners BioMedPartners coparion Frazier Life Sciences Fund+Nextech Invest +2 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Abata Therapeutics Santi TherapeuticsAngitiaCardurion PharmaceuticalsLatigo

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 1

1 acquisitions

Tubulis GmbHacq. by Gilead Sciences

Portfolio news

latest coverage across their companies

Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth - Triveni Bio

Triveni · triveni.bio · Jun 17, 2026

Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases - Odyssey

Odyssey Therapeutics · odysseytx.com · Sep 10, 2025

Frequently asked questions

How many investments has Ascenta Capital made?: Ascenta Capital has 18 tracked investments, 1 of which have exited, including 3 dated in the last 24 months.
What stage does Ascenta Capital invest at?: Ascenta Capital invests at the Seed, Series A, Series B stages.
What is Ascenta Capital's typical check size?: Ascenta Capital typically writes checks of $15M – $30M.
What sectors does Ascenta Capital focus on?: Ascenta Capital focuses on Biotech, Healthtech.
Where is Ascenta Capital located?: Ascenta Capital is headquartered in Wilmington, US.
Does Ascenta Capital lead rounds?: Ascenta Capital has led 4 of the 4 rounds where its role is on record.
Who does Ascenta Capital co-invest with?: Ascenta Capital most often shares deals with OrbiMed, Lightspeed Venture Partners, RA Capital, among 40 tracked co-investors.

Similar investors

Capricorn Venture Partners

Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.

$270K – $10.8M

Sofinnova Ventures

Sofinnova is an investment firm focused on the life sciences and biotechnology sector, partnering with companies from inception through drug development, regulatory approval, company building, and IPO.

$100K – $15M

Versant Ventures

Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.

$250K – $5M

Legendary Ventures, Llc.

Legendary Ventures is a venture capital firm focused on consumer, retail, and technology (CRT) companies, combining the expertise of venture capitalists and retail executives to support portfolio companies and identify acquisition partners.

Kaiser Permanente Ventures

Kaiser Permanente Ventures is the corporate venture capital arm investing in healthcare companies that address real needs and deliver value for patients, providers, healthcare delivery systems, and communities.

$2M – $5M